The abstract is read at the publisher; the summary is JClub's.
A genome-informed risk assessment (GIRA) has been returned to 23,840 participants and their providers in eMERGE, enabling a prospective evaluation of adoption and downstream outcomes over 12 months.
- Why it matters: Real-world evidence is limited on whether genomic risk assessment changes clinical decision-making and health outcomes, creating a critical gap for genomic medicine implementation.
- What they did: The study tests pre-specified outcomes (adoption of recommended actions, new diagnoses, treatment changes, and clinical outcomes) using high-risk vs not-high-risk comparisons, with regression discontinuity for PRS/IRS thresholds and logistic regression for monogenic and family-history stratification.
- The result: With 23,840 participants and 12 months follow-up, the design is powered to detect 2%-11% differences with 80% power (α=0.05) for adoption, while longer follow-up is needed for diagnosis, treatment, and clinical events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.